Helping patients save on KRAS G12C testing

KRAS G12C occurs in 13% (approximately 1 in 8) of non-squamous patients, second only to EGFR mutations.1 Understanding your patients’ KRAS status may help inform your patient's treatment plan.

Biomarker Assist saves on the types of test that identify the KRAS G12C mutation:

Most Medicare, Medicaid, and commercial insurance help patients save on the types of biomarker tests. However, all of the out-of-pocket cost may not be covered. That's where Biomarker Assist can help.

Next Generation
Sequencing (NGS)2
Testing
  • Identifies a panel of biomarkers, including KRAS G12C
  • Results typically within 4-14 days* after submitting materials3-6
NGS Affordability Program
  • For eligible patients with commercial insurance
  • Patient enrolls after test is performed and receives EOB
  • Patients are reimbursed for their out-of-pocket cost of the NGS test

Learn more about the NGS
Affordability Program

KRAS Single Gene
Test (SGT)2
Testing
  • Identifies mutations in the KRAS gene
  • Results typically within 7 days after submitting materials3-5
KRAS SGT Program
  • For patients with all types of insurance plans—commercial, Medicare, Medicaid, and no insurance
  • HCP submits request form before test is performed
  • No cost to patients

Learn more about the
KRAS SGT Program

*CAP/IASLC/AMP Guidelines recommend a turnaround time of no more than 10 days.7

For more information about KRAS G12C and details about testing, please visit www.findkrasg12c.com.

Frequently Asked Questions

  • What is Biomarker Assist?

    Biomarker Assist is comprised of two programs, Next Generation Sequencing (NGS) Affordability Program and KRAS Single Gene Test (SGT) Program. Please refer to subsequent questions for more details on each program. Programs valid for testing performed through December 31, 2021.

  • What is the Biomarker Assist NGS Affordability Program?

    The Biomarker Assist NGS Affordability Program may help eligible, commercially insured patients lower out-of-pocket costs for their NGS biomarker test, including deductible, co-insurance, and co-payment. Eligible patients may pay as little as $0 out-of-pocket for their NGS biomarker test, up to the program maximum of $1000. There is no income requirement for the Biomarker Assist NGS Affordability Program.

    This is a summary; please see full terms and conditions for program requirements and limitations.

  • What is the Biomarker Assist KRAS Single Gene Test Program?

    The Biomarker Assist KRAS Single Gene Test Program is a voucher program to cover the costs of the KRAS Single Gene Test prescribed to your patient. To utilize the program, you will need to fill out the Biomarker Assist KRAS Single Gene Test request form and send it to the lab via fax or mail along with your pathology report and biopsy sample. Once all requirements are received by the lab, the lab will conduct the KRAS Single Gene Test on the sample and send the results to you within 7 days at no cost to you or the patient.

    This is a summary; please see full terms and conditions for program requirements and limitations.

  • Who is eligible for Biomarker Assist?

    The Biomarker Assist NGS Affordability Program is available for eligible, commercially insured patients with advanced or metastatic (stage IV) non-small cell lung cancer with NGS biomarker test coverage (this program covers eligible patient's out-of-pocket obligations after insurance coverage).

    The Biomarker Assist KRAS Single Gene Test Program is available for any patient with advanced or metastatic (stage IV) non-small cell lung cancer regardless of insurance type or status.

Program limitations apply, please see terms and conditions including limits on individual program coverages. Programs valid for testing performed through December 31, 2021.

References: 1. Data on file, Amgen; [Analysis of AACR Genie v8]. 2. Sherwood JL, et al. ESMO Open. 2017;2:e00235.doi:10.1136/esmoopen-2017-000235. 3. Pennell NA, et al. Am Soc Clin Oncol Educ Book. 2019;39:531-542. 4. Timar J, et al. Cancer Metastasis Rev. 2020. doi:10.1007/s10555-020-09915-5. 5. LabCorp. https://www.labcorp.com/tests/481075/i-kras-i-gene-mutation-analysis-extended. Accessed November 4, 2020. 6. Gregg JP, et al. Transl Lung Cancer Res. 2019;8(3):286-301. 7. Lindeman NI, et al. Arch Pathol Lab Med. 2018;142(3):321-346.